Home/Pipeline/G-NK cells

G-NK cells

Multiple Sclerosis

Phase 1Active

Key Facts

Indication

Multiple Sclerosis

Phase

Phase 1

Status

Active

Company

Indapta Therapeutics

About Indapta Therapeutics

Indapta Therapeutics is a private, clinical-stage biotech harnessing a unique subset of natural killer cells, known as G-NK cells, for off-the-shelf cellular immunotherapy. Founded in 2018, the company is advancing its platform into Phase 1 trials for hematologic cancers (in combination with monoclonal antibodies) and multiple sclerosis. With backing from prominent venture capital firms and a seasoned leadership team, Indapta aims to address significant limitations in current autologous cell therapies and autoimmune disease treatments.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
Evobrutinib	EMD Serono	Phase 3	Active